Risk factors, antithrombotic treatment and outcome in retinal vein occlusion: an age-related prospective cohort study
Corresponding Author
Maria Teresa Sartori
Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
Correspondence Maria T. Sartori, MD, 2nd Chair Internal Medicine, Department of Cardiac, Thoracic & Vascular Sciences, Via Giustiniani 2, 35128 Padova, Italy. Tel: +390498212653; Fax: +390498218731; e-mail: [email protected]Search for more papers by this authorSofia Barbar
Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
Search for more papers by this authorAnnalisa Donà
Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
Search for more papers by this authorStefano Piermarocchi
Ophthalmology Unit, Department of Neurosciences, University of Padua, Padua, Italy
Search for more papers by this authorElisabetta Pilotto
Ophthalmology Unit, Department of Neurosciences, University of Padua, Padua, Italy
Search for more papers by this authorGraziella Saggiorato
Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
Search for more papers by this authorPaolo Prandoni
Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
Search for more papers by this authorCorresponding Author
Maria Teresa Sartori
Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
Correspondence Maria T. Sartori, MD, 2nd Chair Internal Medicine, Department of Cardiac, Thoracic & Vascular Sciences, Via Giustiniani 2, 35128 Padova, Italy. Tel: +390498212653; Fax: +390498218731; e-mail: [email protected]Search for more papers by this authorSofia Barbar
Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
Search for more papers by this authorAnnalisa Donà
Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
Search for more papers by this authorStefano Piermarocchi
Ophthalmology Unit, Department of Neurosciences, University of Padua, Padua, Italy
Search for more papers by this authorElisabetta Pilotto
Ophthalmology Unit, Department of Neurosciences, University of Padua, Padua, Italy
Search for more papers by this authorGraziella Saggiorato
Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
Search for more papers by this authorPaolo Prandoni
Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
Search for more papers by this authorAbstract
Objectives
Antithrombotic treatment for retinal vein occlusion (RVO) is controversial, although RVO has been surmised as a predictor of a subsequent vascular event. We aimed to evaluate risk factors, the effects of antithrombotic therapy and the occurrence of subsequent vascular events in patients with a first episode of RVO, according to age of RVO onset.
Methods
In this prospective cohort study, patients with central (CRVO) and branch RVO (BRVO) confirmed by fluorescein angiography were studied; they were divided according to age. Cardiovascular risk factors and thrombophilia were evaluated. Anticoagulants or aspirin were given for at least 3 months. Patients were followed every 6–12 months and vascular events were recorded.
Results
One hundred CRVO and 32 BRVO patients were enrolled. Five of 60 (8.3%) patients <50 yr and 4/72 (5.5%) over 50 yr had a hereditary thrombophilic defect. One or more cardiovascular risk factors were found in 35 (58%) patients of the younger group, and in 66 (91%) of the older group (P < 0.001). Antithrombotic treatment led to both a satisfactory recanalization of occluded veins and visual acuity improvement especially in younger patients. Vascular events occurred in 19 (14%) cases after 4 ± 3.3 yr from RVO, more frequently in older than in younger patients (22% vs. 5%, P = 0.005).
Conclusions
Distribution of cardiovascular, but not of thrombophilic risk factors seems to be influenced by age in RVO patients. Patients with a first RVO, especially those >50 yr, are likely at risk of a subsequent vascular event.
References
- 1Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117: 313–9.
- 2Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133–41.
- 3Cheung N, Klein R, Wang JJ, Cotch MF, Islam AF, Klein BE, Cushman M, Wong TY. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multi-ethic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008; 49: 4297–302.
- 4Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006; 124: 726–32.
- 5Klein BA, Olwin JH. A survey of the pathogenesis of retinal vein occlusion. Arch Ophthalmol 1956; 56: 207–47.
- 6Battaglia Parodi M, Bandello F. Branch retinal vein occlusion: classification and treatment. Ophtalmologica 2009; 223: 298–305.
- 7Yau JWY, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 2008; 38: 904–10.
- 8Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 61–77.
- 9Di Capua M, Coppola A, Albisinni R, Tufano A, Guida A, Di Minno MND, Cirillo F, Loffredo M, Cerbone AM. Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis 2009; 30: 16–22.
- 10O'Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008; 126: 692–9.
- 11 The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114: 545–54.
- 12 The Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993; 116: 286–96.
- 13Weger M, Renner W, Steinbrugger I, Cichocki L, Temmel W, Stanger O, El-Shabrawi Y, Lechner H, Schmut O, Haas A. Role of thrombophilic gene polymorphisms in branch retinal vein occlusion. Ophtalmology 2005; 112: 1910–5.
- 14Arsene S, Delahousse B, Regina S, Le Lez ML, Pisella PJ, Gruel Y. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 2005; 94: 101–6.
- 15Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021–6.
- 16Rehak M, Rehak J, Müller M, et al. The prevalence of activated protein C resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. Thromb Haemost 2008; 99: 925–9.
- 17Marcucci R, Bertini L, Giusti B, Brunelli T, Fedi S, Cellai AP, Poli D, Pepe G, Abbate R, Prisco D. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86: 772–6.
- 18Rehak M, Müller M, Scholz M, Wiercinska J, Niederwieser D, Wiedemann P. Antiphospholipid syndrome and retinal vein occlusion: meta-analysis of published studies. Ophthalmologe 2009; 106: 427–34.
- 19Rubinstein K, Jones EB. Retinal vein occlusion: long-term prospects: 10 years' follow-up of 143 patients. Br J Ophthalmol 1976; 60: 148–50.
- 20Cugati S, Wang JJ, Knudtson MD, Rochtchina E, Klein R, Klein BE, Wong TY, Mitchell P. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007; 114: 520–4.
- 21Tsaulomas MD, Kirwan J, Vinall H, O'Leary MB, Prior P, Kritzinger EE, Dodson PM. Nine year follow-up study of morbidity and mortality in retinal vein occlusion. Eye 2000; 14: 821–7.
- 22Elman MJ, Bhatt AK, Quinlan PM, Enger C. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990; 97: 1543–8.
- 23Mansour AM, Walsh JB, Henkind P. Mortality and morbidity in patients with central retinal vein occlusion. Ophthalmologica 1992; 204: 199–203.
- 24Ho JD, Liou SW, Lin HC. Retinal vein occlusion and the risk of stroke development: a five-year follow-up study. Am J Ophthalmol 2009; 147: 283–90.
- 25Glacet-Bernard A, Zourdani A, Milhoub M, Maraqua N, Coscas G, Soubrane G. Effect of isovolemic hemodilution in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2001; 239: 909–14.
- 26Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 1994; 118: 421–9.
- 27Houtsmuller AJ, Vermeulen JA, Klompe M, Zahn KJ, Henkes HE, Baarsma GS, Tijssen J. The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 1984; 15: 219–29.
- 28Ageno W, Cattaneo R, Manfredi E, et al. Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. Thromb Res 2010; 125: 137–41.
- 29Farahvash MS, Moghaddam MM, Moghimi S, Mohammadzadeh S. Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. Can J Ophthalmol 2008; 43: 79–83.
- 30Pinna A, Simula P, Zinellu A. Subcutaneous nadroparin calcium in the treatment of recent onset retinal vein occlusion: a pilot study. J Ocul Pharmacol Ther 2012; 28: 448–54.
- 31Lazo-Langner A, Hawel J, Ageno W, Kovacs MJ. Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica 2010; 95: 1587–93.
- 32Squizzato A, Manfredi E, Bozzato S, Dentali F, Ageno W. Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. Thromb Haemost 2010; 103: 271–6.
- 33Hattenbach LO, Friedrich Arndt C, Lerche R, Scharrer I, Baatz H, Margaron F, Richard G, Behrens-Baumann W, Ohrloff C. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina 2009; 29: 932–40.
- 34Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198–202.
- 35Rehak J. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008; 33: 111–31.
- 36Marcucci R, Sofi F, Grifoni E, Sodi A, Prisco D. Retinal vein occlusions: a review for the internist. Intern Emerg Med 2011; 6: 307–14.
- 37Kuhli-Hattenbach C, Scharrer I, Lüchtenberg M, Hattenbach LO. Coagulation disorders and the risk of retinal vein occlusion. A subgroup analysis. Thromb Haemost 2010; 103: 299–305.
- 38Lattanzio R, Sampietro F, Ramoni A, Fattorini A, Brancato R, D'Angelo A. Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina 2006; 26: 65–70.
- 39Farahvash MS, Moradimogadam M, Farahvash MM, Mohammadzadeh S, Mirshahi A. Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial. Arch Iran Med 2008; 11: 418–22.
- 40Leoncini G, Bruzzese D, Signorello MG, Armani U, Piana A, Ghiglione D, Camicione P. Platelet activation by collagen is increased in retinal vein occlusion. Thromb Haemost 2007; 97: 218–27.
- 41Leoncini G, Signorello MG, Segantin A, Giacobbe E, Armani U, Piana A, Camicione P. In retinal vein occlusion platelet response to thrombin is increased. Thromb Res 2009; 124: 48–55.
- 42Christoffersen N, Gade E, Knudsen L, Juel K, Larsen M. Mortality in patients with branch retinal vein occlusion. Ophthalmology 2007; 114: 1186–9.